Woodline Partners’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMRX
Woodline Partners's AMRX Position: Q3 2026 in Review
Woodline Partners opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2026: 482,264 shares worth $9.7M. The stake represents 0.03% of the portfolio and ranks #563 among its holdings. This is a return to the name: Woodline Partners previously reported a position in AMRX as recently as Q1 2025.
Woodline Partners first reported a position in AMRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $13.3M in Q3 2024. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.
- Woodline Partners held 482,264 shares of Amneal Pharmaceuticals worth $9.7M as of Q3 2026.
- Amneal Pharmaceuticals was a new Woodline Partners position in Q3 2026.
- Amneal Pharmaceuticals made up 0.03% of Woodline Partners's portfolio in Q3 2026, its #563 holding.
- Woodline Partners first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
- Woodline Partners's Amneal Pharmaceuticals position peaked at $13.3M in Q3 2024.
- 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.